but i don't think you go and buy gilead right here. >> would you prefer a trade on ibb? >> a few are the ib right here. those are the names i want to be in. i wouldn't want to be these small cap stuff. >> it's all driven by the names you mentioned, a few others short. >> absolutely. got a question out there. send us a tweet at "options action." for everything "options action" only one place to go. optionsaction@cnbc.com. sign up for the newsletter. some have likened it to "war and peace." it's simply called a great read. here's what's coming up next. >>> coming up, are gm investors about to get a few prize? >> a new car! >> actually, we're talking about something even more exciting, a potential deal. we've got a special report. >>> and are goggle shares about to soar? no need to ask jeeves. because we got the trade right here. stick around for more "options action." . ahh... steve, other than making me move stuff, what are you working on? let me show you. okay. our thinkorswim trading platform aggregates all the options data you need in one place that lets you visualize

i'm liking at gilead, this is a company that has more than doubled its revenues in the last two years. it's trading 11 times next 12 month anticipated earnings. so what you actually have here is a growth story trading cheap. so when i look at this space, i think there aren't a lot of places you can kick around value and find growth in the market right now. this is one of them. >> what is your trade. >> >> the simple trade is to go to july, look at the 115 call data. sell the 120s for 89 cents. this is a way you can do like dan with the put spread on cat, to make a bullish bet and risk a small percentage of what the stock costs. >> that's exactly it. you are risking a small percentage, up 19% on the year. this is a $100 billion market cap. they did say they've doubled their sales in the last two years. courter failed to mention one thing. stocks sold off in late december 20% and 10% in february. i think it's a crowd stock. i do believe it's obviously pepsi is going to be a massive, massive market. when you lookal sales expectations gr going forward, if the pricing issues come back in h

gilead. >> dan? >> caterpillar.his is one -- i want to press this short, you wait for a little bit of a bounce, target august, that's the earnings event. >>> looks like our time has expired. thanks for watching. i'm melissa lee. check out the web site and also, of course, check out our daily segment "inside fast money." see you back here next friday at 5:30. make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere and i promise to help you find it. "mad money" starts right now. welcome to "mad money" and i'm trying to savia a little money. my job is to save you money and educate you. so, call me or tweet me at jim cramer. if you didn't know any better, you might think the federal reserve should be cutting rates

look at the recent run gilead has had. everybody buried this company a few times over the last nine months and here we are trading 110ish and cell gene as well. amgen can't get out of its way. they have an incredible pipeline and drugs out there already. in order, cell gene gilead amgen. >> the one thing about the stocks is the dividend. when you see this move people look at these stocks and say this is something i've been looking for an opportunity to get back in. 62 on bristol-myers is the level. >>> let's get to the other big mover in today's session, that would be oil. crude climbing more than 4% settling above 60 bucks a barrel but is today's spike a precursor to a larger move higher ahead of next friday's opec's meeting. the global head of energy analysis at oil price energy service joins us. tom, great to have you with us. the expectation is that nothing is going to happen at this opec meeting, correct? >> oh i think that's the reasonable expectation. all the rhetoric from the saudi, the kuwaitis, the emirates has i

and then big drug name, gilead, up with 8% higher. so it has momentum and you can see here the longer term chart as well showing some signs of strength here over the past year, up by about 34%. so three names, momentumish in nature. all it be modest. >> thanks so much, dom chu. steve, where would you go? >> if you look back on amazon, you had the huge gap higher. it's closing that gap. almost 50% retracement. it has a little bit more room to fall, but amazon, you have to look at the cloud presence. i would still an buyer. >> quit thoughts on tesla. 250 seems a level it cannot hold. >> i'd say it's running out of steam. i think you'd probably see a pull back at 220. but i wouldn't be buying at 250. >> i'm actually long gilead. stock was up a few bucks, but that was a blowout number. because really the earnings thumb was fantastic and the stock didn't really react. now it's up about 7, 8 bucks. not expensive here. so i like gilead. >> type for pops and drops movers. go pro oigopro. >> upgraded. the street is liking it better now that it

gilead can go higher here.ne was as disappointing as gilead was good. >> we'll get ford numbers in a moment for april and cramer's mad dash as we count down to the opening bell. one more look at the premarket as we kick off may. more "squawk on the street" ahead. ahead. the promise of the cloud is that every organization has unlimited access to information, no matter where they are. the microsoft cloud gives our team the power to instantly deliver critical information to people, whenever they need it. here at accuweather we get up to 10 billion data requests every day. the cloud allows us to scale up so we can handle that volume. we can help keep people safe and to us that feels really good. why do we do it? why do we spend every waking moment, thinking about people? why are we so committed to keeping you connected? why combine performance with a conscience? why innovate for a future without accidents? why do any of it? why do all of it? because if it matters to you it's everything to us. the xc60 crossover. fr

it's sitting, gilead at $102 a share.eath that in the options today, november 75 puts. huge activity there. now that's 25 some odd, $27 out of the money right now but they're going out to november buying some time. it makes you wonder if somebody's just putting out a spec play. 11,000 of these trades for about $1. look, if this cracks these will actually start to move. they would be right. if this stock can crack and it cracks underneath those averages, watch out below. i think gilead even though it's cheap and i like the name i like the pipeline, if it breaks it has a long ways to fall. >>> coming up fed chair janet yellen shocking the street. up next why yellen's warning to the world could be a contrary sign to buy the stocks. plus tesla up. elon musk ready to take the stage. the comments from the man himself when we return. >>> coming up on the second half of "fast money" elon musk just kicking off the tesla earnings call. we have team coverage ready to provide instant analysis. we'll also be hearing from the man himse

charles: i'll go with gilead. that number last night was an amazing, amazing beat.e people quibbled that a lot of it came from one big drug. so what? a big, huge beat. anybody worried here about next week and the earnings. we'll get back into it. real quick. something that really stands out. would alibaba be the one that moves the needle? matt: i don't think that will move it. i'm looking at cvs. only because it's weighted to the u.s. without the dollar effect. they should do well. if not, says something about consumers in the us. charles: we talked a lot about cvs this weekend. we had big news of the freddie gray death. the six officers charged with murder. huge protests, a lot in simpa hsympathy with baltimore. oakland, portland, philadelphia, and many more. we'll be right back. >> comprehensive, thorough and independent investigation, coupled with the medical examiner's determination that mr. gray's death was a homicide, which we received today, has led us to believe that we have probable cause to file criminal charges. >> yes! charles: that was freddie gray's de

and biotech got a much needed relief from gilead. the nasdaq, the ibb, rallied very nicely.utting the breaks on a tumble that began when they hit a double-top. all right guys. a huge day a huge week. the action never, never stopped. i'm charles payne. and you're watching "making money." let's do it. let's talk to the investment pros. chris. core portfolio. regina is back with us. nice to have you back. susan our small business expert. hilary kramer a&g capital. and matt mccaul. let's do it. let's dig into this market. now, maybe just maybe it looks like again the market may have dodged a bullet. here's the question: one of the old axioms, sell in may and go away. matt: every time the market subpoena steve is not on. charles: he's been sick. matt: i'm not buying into the old adage. it's too easy to sell in may. if you look back 100 years, it does make sense. recently, it doesn't work well. we're in the tightest trading range so far. the economic numbers this morning, i don't see anything that will break us big to the upside and downside. manufacturing was absolutely terrible.

> they have moves for spending on these drugs and making waves in hepatitis c to exclude those by gilead and get a discount by ab v. and also with cancer where list prices can top 10,000 dollars a month. for "nightly business repor i'm meg terrell. >> coming up can an in vestment banker by trade find the next best thing on a pig farm? his story, coming up next. >>> here is what to watch tomorrow. we'll have results from more retailers including nordstrom and kohl's. on the data front, the consumer price index will be out,s in important indicator and jobless claims and that is what is on the agenda for thursday. >> facebook wants to give the low wage workers a pay raise. it will require the contractors and vendors to pay employees at least $15 an hour. facebook wants the employees to get at least 15 paid days off annually for holidays sick days and if they don't get paid patiental leave they move they get a 4,000 dollars bonus, bringing attention to the wage gap in silicon valley. >> japan's biggest carmakers will investigate worldwide, recalling 6.5 million calls, honda didn provide deta

." >> cbs morning rounds sponsored by gilead gilead proud sponsor of hepatitis awareness month.e may be no symptoms for years. no wonder you try to push it to the back of your mind and forget it. but here's something you shouldn't forget. hepatitis c is a serious disease. if left untreated, it could lead to liver damage and potentially even liver cancer. if you are one of the millions of people with hepatitis c you haven't been forgotten. there's never been a better time to rethink your hep c. because people like you may benefit from scientific advances. advances that could help cure your hep c. visit hepchope.com or call to talk to a hep c educator who can help answer your questions and work with you to create a personalized plan to prepare you for a conversation with your hep c specialist. my cut hurt. mine hurt more. mine stopped hurting faster! neosporin plus pain relief starts relieving pain faster and kills more types of infectious bacteria. when you pick any 3 participating products get a free all better bag. available at walmart. ♪ [music] ♪ jackie's heart attack didn't

it started with hepatitis c where they negotiated a discount to provide a regiment from gilead and others and now the focus is cancer drugs for which costs in the u.s. topped $100 billion last year. >> oncology is a hot button topic in terms of the ore all -- over all cost of drugs steadily rising to the point where we're used to seeing drugs well in necessary of 100,000 dollars per patis been along with everything in the drug sector a growing noise around the ever increasing price of drugs. >> the plan has two parts. the first focuses on how well drugs are shown to work in different cancers. dr. steve miller cites a drug called tars eva. it has proven in trials to extend patients lives by months for lung cancer and only a couple of weeks for pancreatic so the plan would reimburse more for the first. how well it works for individual patients and that would require testing and monitoring patients for treatment. they have enlisted outside experts to evaluate it on the drugs and health plans have already signed on. brian scorny points out a similar system is employed in europe where governme

but then at the end of last year gilead's own combination pill harvoni was approved.hs it brought in $2 billion in revenue. that may lead to the erosion analysts are modeling for olysio. they do cure this disease. new generations of drugs have been coming on the market so fast. j & j reiterated its commitment to the hepatitis c space announcing a deal with gilead. >> back to you guys. >> good stuff. it's good for patients if nothing else. >> absolutely. >>> heading to the close, 20 minutes to go in the trading session here. early on we talked about record highs for the dow and the s&p. doesn't look like that's going to happen at least for the moment. the industrial average is now down 26 points with the s&p down more than a point and a half. >>> up next on the heels of today's fed minutes, the rate hike debate rages on. what should fed chair janet yellen do and when should she do it? that debate here on "closing bell" when we come right back. >>> welcome back. earnings moving this market today. we'll start with etsy down 19% after last night's disappointing report. lo

drugmaker gilead saw its income nearly double. visa says its income fell by 3% to start the year but that was still enough to beat what analysts expected. and linkedin stock is down 20% in after-hours trading. a disappointing forecast for the spring sent its stock plummeting. >>> even though yahoo did not perform as expected, ceo marissa mayer still raked in some $42 million last year. mayer was docked $900,000 from her bonus and 12.4 million from her stock rewards. she did okay though. the company's board sets performance goals each year for its executives. >>> it is 4:57 right now. tesla launches batteries to power homes. how the new technology may be a game changer to the solar industry. >> reporter: a day of protests planned today in several bay area cities and some of those protests mi >>> good morning, everyone. it's friday, may 1. i'm michelle griego. >> hi, everyone. i'm frank mallicoat. happy friday. it is nearly 5:00. may day protests and demonstrations are planned around the bay area this morning. anne makovec is live i

. >>> gilead sciences declared first quarterly cash dividend 43 cents a share. that came along with the drug maker's earning results better than estimates. after the close, the stock popped initially. before the bell shares fell along with the market. almost 2% to $100.54. >>> biotech stocks may be having a hard time of late but the same cannot be said about the city where many of them are headquartered. cambridge, massachusetts, not only home to two of the world's greatest universities, harvard and m.i.t. also kendall square now known as biotech's capital city. and as more biotech companies move to that area big money is following. me >> it's a couple blocks away. everything is a couple blocks away. entrepreneur mike gelman doesn't have to go far for board meetings. smack in the middle of one of the biotech industry's capital cities in marquee neighborhood of kendall square. with 130 life science companies in 2.5 square miles, the neighborhood surm.i.t. lays claim to the densest concentratio of biotech in the world and as the industry boomed in recent years, so

sponsored by gilead. of hepatitis awareness month. push it to the back of your mind and forget it. but here's something you shouldn't forget. hepatitis c is a serious disease. if left untreated, it could lead to liver damage and potentially even liver cancer. if you are one of the millions of people with hepatitis c you haven't been forgotten. there's never been a better time to rethink your hep c. because people like you may benefit from scientific advances. advances that could help cure your hep c. visit hepchope.com or call to talk to a hep c educator who can help answer your questions and work with you to create a personalized plan to prepare you for a conversation with your hep c specialist. listen up... i'm reworking the menu. veggies you're cool... mayo, corn dogs... you are so out of here! ahh... the complete balanced nutrition of great tasting ensure. with nine grams of protein... and 26 vitamins and minerals. and now with... ...twice as much vitamin d ...which up to 90% of people don't get enoug

look at what they did with gilead. they kept them off the formulary. o of solving the issues here. we're a big part of the company. if you want to play it, that's the one to be involved in. >> tune in to "making money" tomorrow night. charles, he won't be here. he and the crew they're out in las vegas. at the money show. they'll be live from that show. they'll have investment lessons from you. we'll be answering questions from a live studio audience. that's tomorrow night at 6 o'clock right here on fox business. meantime, earnings out tomorrow. children's place and nordstrom. what does the panel think of these companies and how will they do? that's coming up. ♪ tom: tomorrow we'll look at earnings, children's place, and nordstrom. heatha, you shop at nordstrom i am sure. and children's place. >> i think nordstrom is well, they have great product, they did miss estimates last quarter, part of 2015 guidance they were guiding lower because of ongoing costs because of the other investments they were making withins company, they are investing in digital. we

drugmaker gilead saw its income nearly double. visa says its income fell by 3% to start the year.o beat what analysts expected. linkedin stock is down 20% in after-hours trading. a disappointing forecast for the spring sent its stock plummeting. >>> and it was a down day overall for the markets. the dow was down 195. nasdaq down 82. s&p was off by 21. >>> even though yahoo didn't perform as expected, ceo marissa mayer still raked in $42 million last year. mayer was docked $900,000 from her bonus and $12.4 million from her stock awards. the company's board sets performance goals each year for its executives. >>> coming up, stranded in san francisco. what it took to wrangle this little sea lion found just wandering around on the sidewalk. >> some professional franchises cannot get 10,000 people to a game. the san francisco 49ers have 10,000 folks here for a draft party! how about that? we are live in santa clara as the 9ers are about to make their pick. that's coming up. >> and i'm dennis o'donnell. coming up, did the raiders score in today's nfl draft? >> with the fourth pick, the

you would ask would they lower their price after recouping their r&d dollars, a chief executive at gileadighly unlikely. gerri: thank you dr. campbell. to one of my favorite topics, food. activists are calling for the government to play a larger role in re-- meat. peter barnes is joining us. >> that is right here at is a -- sakowski's meat market, a group has gotten together to lobby the government to include less meat in the official government dietary guidelines, not just for health reasons but also for the environmental reasons. saying it is better to grow crops on farmland than it is livestock. they have launched a campaign, my plate-my planet, they argue quote that the science is clear, eating less meet and more plant is better for our health, the meat industry has launched a campaign called, hands off our hot dogs. which argues, the the confirms that -- the customers who come here, they come here to buy meat, they agree. >> probably have a steak once a week i eat more chicken and pork. and environmental effect is not the best but i don't see the harm in it as long as you stay health

gilead spent $11 billion to buy farm asset which had no revenues to speak of, but had one for help "c." overvalued? i don't think so. if you want to go a -- go ahead and take something off the table because of yellen's amorphous warning but greenspan didn't tell us when to get back in in '96 and yellen was plain wrong about biotech. don't let her call freak you out. i think she's terrific at running the federal reserve, but when it comes to making the calls on the stock market she's 0 for 1. don't take your investment advice from the chief of the federal reserve of the united states. tony? >> caller: booyah from california. >> beautiful out there. how can i help you? >> caller: well, we can use some rain, but mcdonald's made the news big this week with their recovery plan but meanwhile, burger king and tim horton are growing their sales nicely. they're owned by a canadian company restaurant brands international. whose profits have been trading in the narrow range. so jim, are there problems with qsr -- >> no, no. qsr is good. it isn't just a class. look at wendy's. that was stellar. w

gilead is a consoleationeidationconsolidation. this is until it started to see mergers like the micro combination now qurvo and cypress expansion deal and annex semi conductors and the acre session of lsi. these companies competed against each other head the to head and boy, they were just killing each other. or to present themselves as a one-stop shop after a the mergers. that's why when i first heard that intel was in talks to buy altera a makes a ton of safe. intel needs to open, more inl property and needs to be a bigger player in the high-tech companies, not just personal commuters. i think that even if intel offer add high praise altera would be good for the company stock and altera balked and my colleague told me that they are talking again and inst's principle to principle this is a huge deal to spur more consolidation as we learned that the vago is taking a hard look at buying altera competitors and they disappointed many times in the earnings or integrated products. it doesn't matter. how important are the deals? i don't

and biotech got a much needed relief from gilead. the nasdaq, the ibb, rallied very nicely.aks on a tumble that began when they hit a double-top. all right guys. a huge day a huge week. the action never, never stopped. i'm charles payne. and you're watching "making money." let's do

and with the help of an amazing quarter from gilead all things biotech, too. i don't think we're out of the selling woods, because we're in a conundrum here. most of the year, investors have favored the stocks of the companies just doing business in u.s. that makes sense since they don't sell overseas and weren't hurt by the fall of the u.s. dollar. but in april, the same stocks lost their tailwinds and, therefore, their luster. that means we see today investors have become wary of the same domestic stocks they loved just four weeks ago. at the exact same time investors had fallen head over heels for companies that benefit from cheaper gasoline. however in april it rose 25%, its biggest rally in years, so those stocks fell out of favor, too. nevertheless, it's another like the companies that sell overseas are doing well, at least not yet. the international plays have tremendous earnings risk. tut it all together and pretty much everything became treacherous during the seat change that sent oil up and the dollar down. no group fit into the script of what was in

gilead is out and we're looking good. there's a lot of room to be good tactically.ryone loves copper and everyone is buying up the metal stocks, you want to be the guy not in pain. you want to be ready to jump on opportunities. like biotech on the short side. yields start to go up, off of rock, rock, rock bottom, below rock, bedrock bottom. that market gets a little unravelled, too. >> i don't think it's going to get unravelled, i think what you're seeing there, scott, is a reflection of some economic growth in europe. better than expectations were at the beginning of the year. i want to point one thing out. the whole sell in may, at least as i've always grown up with it is, you sell in may and you come back in september. that's what i'm remembering to as far as a thesis that just doesn't get borne out by the evidence. we've had nice summer rallies for the past few years, i'm not selling in may and going away. >> mike santoli, you're talking about disney as one to watch. why? >> disney has been a bulletproof name. had you a 1% decline yesterday in the stock. obvious

. >> gilead popped over. that's the one generation as opposed to amgen and the claims is they have so dependent, look at what brings this down. off this news. >> facebook is taking on google. the company confirming it is starteding to test out and in app search engine to make it easier for users. what could this mean for search team google? do we think pins and needles? >> i definitely think we will. when you consider how much searches, yeah, they're doing it in video, too. they are right up on google's heels here. so i'm not particularly negative on google whatsoever. i'm bullishly positioned in the near term. what if people get upset about facebook spending. every time we have an analyst on that's bullish. they get excited. they have this currency. they have gone out and have mobile messaging. they should be. the only problem i have right now is the stock report is down about 1% from those gap highs after earnings. it kind of feels like it's lost momentum. >> is it only an issue if google is actually losing

yep, >> announcer: this portion of "cbs this morning" sponsored by gilead.epatitis awareness month. you've tried to forget your hepatitis c. it's slow moving, you tell yourself. i have time. after all there may be no symptoms for years. no wonder you try to push it to the back of your mind and forget it. but here's something you shouldn't forget. hepatitis c is a serious disease. if left untreated, it could lead to liver damage and potentially even liver cancer. if you are one of the millions of people with hepatitis c you haven't been forgotten. there's never been a better time to rethink your hep c. because people like you may benefit from scientific advances. advances that could help cure your hep c. visit hepchope.com or call to talk to a hep c educator who can help answer your questions and work with you to create a personalized plan to prepare you for a conversation with your hep c specialist. ♪ there are no medals won for earning a living. it's just what you do for family. but it's hard to build a future if you can't see past today. that's why walmart

ed by gilead. proud sponsors of hepatitis awareness month. et your hepatitis c.t to the back of your mind and forget it. but here's something you shouldn't forget. hepatitis c is a serious disease. if left untreated, it could lead to liver damage and potentially even liver cancer. if you are one of the millions of people with hepatitis c you haven't been forgotten. there's never been a better time to rethink your hep c. because people like you may benefit from scientific advances. advances that could help cure your hep c. visit hepchope.com or call to talk to a hep c educator who can help answer your questions and work with you to create a personalized plan to prepare you for a conversation with your hep c specialist. this allergy season, will you be a sound sleeper, or a mouth breather. well, put on a breathe right strip and instantly open your nose up to 38% more than allergy medicines alone. so you can breathe and sleep. shut your mouth and sleep right. breathe right. advanced design makes it easy to protect your dog or cat from fleas and ticks. discover seres

and frankly, i think, it's time to talk to gilead, the manufacturer of it and basically ask them if they are currently being very generous and providing these drugs hepatitis c drugs to countries like india and the republic of georgia for free. very generous. for whatever reasons they are doing that. but maybe at a time when their profits are soaring maybe they might want to respect the veterans of this country who might die or become much sicker because they don't have access to this wonderful product. and as senator blumenthal mentioned. if they're not prepared to come to the table, i'm not impressed that you're paying $540 a pill. for people who put their lives on the line to defend our country. i would suggest to them, you sit down again with them and tell them that you're prepared to utilize federal law 28usc1998 to break the patents unless they're prepared to come down significantly lower than they are right now. it's not a question of taking money. i know you've requested to take money out of the choice program. maybe that's a good idea. but it is a better idea to have them treat

gilead earnings beat the street as the quarterly profit nearly doubled.nd dreamworks reported a bigger than expected loss. the studio spending money on restructuring and diversifying it's businesses and expedia shares got a boost after the company beat expectations on an increase in travel bookings both inside and outside the u.s. which if you think about it that covers everything except extraterrestrial i think. inside and outside of the u.s. >> they're selling tickets for everything. >> right. now back to becky in omaha. becky beck. did you bring your hair person. >> did i what --? no my friend hilda is here an came with me this morning and angie has done my make up. i'm all set. >> and you have the lightning. >> got the lighting. you're jealous. well, this weekend's meeting is all about berkshire hathaway's businesses and we get a good snapshot of the overall economy here in the united states. they do have international aspects too but when you really want to know what's happening you get to talk to warren buffet about what he thinks is happening in th

. >> reporter: for gilead a nurse here the machine is with m.g you think will make things better for people who have these procedures in the future? >> absolutely. i'm ready to talk to the doctor. i'm ready to find out what they found. >> reporter: and ready to remember what she's told. for "today," joe fryer, nbc news, seattle. >> interesting idea. let's get more on this with dr. natalie azar. good morning to you. >> good morning. >> i can see why this is appealing particularly when you look at the price differences between having an anesthesiologist in the room and the machine. it's a little unsettling. it's like thinking about a plane being flown without a pilot. >> i know. i think that's the natural reaction. it's the natural reaction i had as a doctor and patient that i would want the doctor to administer it. but i think it's important for people to remember what this is for. it has a narrow indication. that is for these procedures for a very very select group of patients. again, for the induction and maintenance of the anesthesia. this is